نتایج جستجو برای: glycosylation end products

تعداد نتایج: 686733  

Background:  Human coagulation factor IX (hFIX) is a glycoprotein with two N-glycosylation sites at the activation peptide. Since the activation peptide is removed in mature hFIX, the exact role of N-glycosylation is unclear. To investigate the role of N-glycosylation in the secretion and activity of hFIX, we inhibited N-glycosylation by tunicamycin in the stable Human Embryonic Kidney (HEK)- c...

Journal: :Curationis 1978
R Bergman

Present-day nursing administration has many goals, roles and functions. Predominant among the roles are those of: programme planner, manager of material resources, man­ ager of human resources, educator, clinician and researcher. These and other roles relate to clients, colleagues, the agency, the community and the profession. The roles are not discrete, but overlap and intertwine with each oth...

2012
Vladimír Jakuš Michal Sapák Jana Kostolanská

The present study investigates the relationship between diabetes metabolic control represented by levels of HbA1c, early glycation products-(fructosamine (FAM)), serum-advanced glycation end products (s-AGEs), lipoperoxidation products (LPO), advanced oxidation protein products (AOPP) and circulating TGF-β in young patients with DM1. The study group consisted of 79 patients with DM1 (8-18 years...

2014
Kaihei OKI Jamyan DUGERSUREN Shirchin DEMBEREL Koichi WATANABE

Here, we used pyrosequencing to obtain a detailed analysis of the microbial diversities of traditional fermented dairy products of Mongolia. From 22 Airag (fermented mare's milk), 5 Khoormog (fermented camel's milk) and 26 Tarag (fermented milk of cows, goats and yaks) samples collected in the Mongolian provinces of Arhangai, Bulgan, Dundgobi, Tov, Uburhangai and Umnugobi, we obtained a total o...

جعفرنژاد, اکبر , فرزامی, بیژن , نخجوانی, منوچهر , گل محمدی, تقی ,

Background: The non-enzymatic glycosylation (NEG) of proteins in diabetes damages both the structure and function of these proteins. In vivo and in vitro studies have shown that NEG of proteins and advanced glycosylation end-products (AGE) contribute to the pathogenesis of both macrovascular, such as atherosclerosis, and microvascular complications, such as retinopathy and nephropathy, in diabe...

2013
Ioscani Jiménez del Val Antony Constantinou Anne Dell Stuart Haslam Karen M Polizzi Cleo Kontoravdi

Introduction Monoclonal antibodies (mAbs) are currently the highestselling products of the biopharmaceutical industry, having had global sales of over $45 billion in 2012 [1]. All commercially-available mAbs contain a consensus N-linked glycosylation site on each of the Cg2 domains of their constant fragment (Fc). The monosaccharide composition and distribution of these N-linked carbohydrates (...

Journal: :Current opinion in biotechnology 2014
Michael Butler Maureen Spearman

Non-human mammalian cells such as CHO have been used predominantly for the production of biopharmaceuticals including monoclonal antibodies (Mabs). Although the glycosylation profile of these products is 'human-like' there is still the possibility of immunogenic epitopes such as α-Gal and Neu5Gc. Human cell lines have now been designed for high productivity of recombinant proteins and ensuring ...

Journal: :The Journal of clinical investigation 1994
I Giardino D Edelstein M Brownlee

Intracellular sugars are more reactive glycosylating agents than glucose. In vitro nonezymatic glycosylation of basic fibroblast growth factor (bFGF) by fructose, glucose-6-phosphate (G6P), or glyceraldehyde-3-phosphate (G3P) reduced high affinity heparin-binding activity of recombinant bFGF by 73, 77, and 89%, respectively. Mitogenic activity was reduced 40, 50, and 90%. To investigate the eff...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید